

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation of its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance with the whole or any part of the contents of this announcement.



VENTUREPHARM LABORATORIES LIMITED

萬全科技藥業有限公司*

(Incorporated in Cayman Island with limited liability)

(Stock code: 8225)

Profit Warning

This announcement is made by the Company pursuant to Rule 17.10 of the GEM Listing Rules.

The Board wishes to inform the Shareholder of the Company and potential investors that the Company is expected to record an unaudited profit increase for the three months ended 31 March, 2009 compared to the unaudited profit for the three months ended 31 March, 2008.

Shareholder and potential investors are advised to exercise caution in dealing in shares of the Company.

This announcement is made by Venturepharm Laboratories Limited (the "Company") pursuant to Rule 17.10 of the GEM Listing Rules.

The board of Directors of the Company (the "Board") wishes to inform the Shareholder of the Company and potential investors that the Company is expected to record an unaudited profit increase for the three months ended 31 March, 2009 compared to the unaudited profit for the three months ended 31 March, 2008. Based on the information currently available, the unaudited profit increase for the three months ended 31 March, 2009 is expected to be mainly attributable to: (1) Foreign exchange gain on the convertible bond issued in Swiss Franc and issued by the Company; (2) Fair value gain resulted from the increase of market price of an available-for-sale financial asset.

This announcement is only based on the preliminary assessment by the management in accordance with the unaudited management accounts of the Company which have not yet been finalized as at the date hereof. Further detail of the performance of the Company will be disclosed when the

unaudited results of the Company for the three months ended 31 March, 2009 are announced.

Shareholder and potential investors are advised to exercise caution in dealing in shares of the Company.

By order of the Board
Venturepharm Laboratories Limited
William Xia Guo
Chairman

Beijing, May 7, 2009

*For identification purpose only

As at the date of this announcement, the Board comprises Mr. William Xia Guo (Chairman) and Dr. Xuemei Song, all of whom are executive Directors; Dr. Tao Feng, Mr. Xin Wu and Dr. Nathan Xin Zhang, all of whom are non-executive Directors; Mr. Hong Bo Wang, Mr. Paul CONTOMICHALOS and Mr. Ming Yu Wu, all of whom are independent non-executive Directors.

This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting.